[{"id":"b90d0390-a592-4a17-be55-4a843bf4b331","acronym":"","url":"https://clinicaltrials.gov/study/NCT03326921","created_at":"2021-01-29T07:15:51.429Z","updated_at":"2024-07-02T16:35:13.551Z","phase":"Phase 1","brief_title":"HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","source_id_and_acronym":"NCT03326921","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • CD4","pipe":" | ","alterations":" HLA-A*02:01","tags":["HLA-A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • HA-1 T TCR T Cell Immunotherapy"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 02/23/2018","start_date":" 02/23/2018","primary_txt":" Primary completion: 10/16/2027","primary_completion_date":" 10/16/2027","study_txt":" Completion: 07/16/2028","study_completion_date":" 07/16/2028","last_update_posted":"2024-03-21"}]